Pompholyx: What's new?

Expert Opinion on Investigational Drugs

Volumn 17, Issue 6, 2008, Pages 897-904

  Wollina, Uwe ^a  

^a ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

Author keywords

Botulinum toxin type A; Calcineurin inhibitors; Corticosteroids; Leukotriene antagonists; Monoclonal antibodies; Phosphodiesterase inhibitors; Pompholyx; Retinoids; Systemic therapy; Topical therapy; UV free phototherapy; UVA 1 phototherapy

Indexed keywords

ALITRETINOIN; ANTIRETROVIRUS AGENT; AZATHIOPRINE; BEXAROTENE; BOTULINUM TOXIN A; CALCINEURIN INHIBITOR; CILOMILAST; CYCLOSPORIN A; DANDELION JUICE; HERBACEOUS AGENT; HYDROCORTISONE; INFLIXIMAB; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHOTREXATE; MOMETASONE FUROATE; MONOCLONAL ANTIBODY; MONTELUKAST; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; N (3,5 DICHLORO 4 PYRIDYL) [1 (4 FLUOROBENZYL) 5 HYDROXY 3 INDOLYL]GLYOXYLIC ACID AMIDE; OMALIZUMAB; PHOSPHODIESTERASE IV INHIBITOR; PIMECROLIMUS; PLACEBO; PRANLUKAST; RETINOID; ROFLUMILAST; TACROLIMUS; TARGRETIN GEL; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

ADJUVANT THERAPY; ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; ATOPY; BLISTER; BURNING SENSATION; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DERMATITIS; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG FORMULATION; ECZEMA; EPIDERMOLYSIS BULLOSA; ERYTHEMA MULTIFORME; HEADACHE; HEAT SENSATION; HERPES; HUMAN; IMMUNOGLOBULIN A DEFICIENCY; IMPETIGO BULLOSA; MEDLINE; MONOTHERAPY; MYCOSIS FUNGOIDES; NONHUMAN; PEMPHIGOID; PEMPHIGOID GESTATIONIS; PHARYNGITIS; PHOTOTHERAPY; PITYRIASIS RUBRA PILARIS; POMPHOLYX; PUSTULAR PSORIASIS; PUSTULOSIS; PUVA; REVIEW; RISK FACTOR; SEPTICEMIA; SIDE EFFECT; SKIN ATROPHY; SKIN BURNING SENSATION; SKIN DISEASE; SKIN IRRITATION; SUBCORNEAL PUSTULAR DERMATOSIS; TACHYPHYLAXIS; TINEA PEDIS; ULTRAVIOLET RADIATION; UNPLEASANT SENSATION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BOTULINUM TOXIN TYPE A; CALCINEURIN; CHILD; CLINICAL TRIALS AS TOPIC; DERMATITIS, OCCUPATIONAL; DOUBLE-BLIND METHOD; DRUG DESIGN; ECZEMA, DYSHIDROTIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOTRIENE ANTAGONISTS; MULTICENTER STUDIES AS TOPIC; PHOSPHODIESTERASE INHIBITORS; PHOTOCHEMOTHERAPY; PUVA THERAPY; RECURRENCE; TRETINOIN;

EID: 45749113739     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.6.897     Document Type: Review

References (54)

1. Lofgren SM, Warshaw EM. Dyshidrosis: epidemiology, clinical characteristics, and therapy. Dermatitis 2006;17(4):165-81
2. Uter W, Gefeller O, Schwanicz HJ. Occupational dermatitis in hairdressing apprentices. Early-onset irritant skin, damage. Curr Probl Dermatol 1995;23:49-55
3. Lehucher-Michel MP, Koeppel MC, Lanteaume A, Sayag J. Dyshidrotic eczema and occupation: a descriptive study. Contact Dermatitis 2000;43(4):200-5
4. Magina S, Barros MA, Ferreira JA, Mesquiti-Guimaraes J. Atopy, nickel sensitivity, occupation, and clinical patterns in different types of hand dermatitis. Am J Contact Dermat 2003;14(2):63-8
5. Meneghini CL, Angelini G. Contact and microbial allergy in pompholyx. Contact Dermatitis 1979;5(1):46-50
6. Pitché P Boukari M, Tchangai-Walla K. Factors associated with palmoplantar or plantar pompholyx: a case-control study. Ann Dermatol Venereol 2006;133(2):139-43
7. Bryld LE, Agner T, Menne T. Relation between vesicular eruptions on the hands and tinea pedis, atopic dermatitis and nickel allergy. Acta Derm Venereol 2003;83(1):186-8
8. Uyttendaele H, Obadiah J, Grossmann M. Dyshidrotic-like spongiotic dermatis after intravenous immunoglobulin therapy. J Drugs Dermatol 2003;2(3):337-41
9. Vocks E, Plötz SG, Ring J. The dyshidrotic eczema area and severity index - a score developed for the assessment of dyshidrotic eczema. Dermatology 1999;198(3):265-9
10. Veien NK, Ølholm Larsen P, Thestrup-Pedersen K, Schou G. Long-term, intermittent treatment of chronic hand eczema with mometasone fuorate. Br J Dermatol 1999;140(5):882-6
11. Pigatto PD, Gibelli E, Fumagalli M, et al. Disodium cromoglycate versus diet in the treatment and prevention of nickel-positive pompholyx. Contact Dermatitis 1990;22(1):27-31
12. Jensen CS, Menné T, Lisby S, et al. Experimental systemic contact dermatitis from nickel: a dose-response study. Contact Dermatitis 2003;49(3):124-32
13. Wollina U. The role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis. Am J Clin Dermatol 2007;8(3):157-73
14. Berger TG, Duvic M, Van Voorhees AS, et al. American academy of dermatology association task force. The use of topical calcineurin inhibitors in dermatology. safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006;54:818-23
15. Bieber T. Cork M, Ellis C, et al. Pediatric Advisory Committee of the Food and Drug Administration. Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatology 2005;211(2):77-8
16. Schnopp C, Remling R, Möhrenschlager M, et al. Topical tacrolimus (FK 506) and mometasone furoate in treatment of dyshidrotic palmar eczema: a randomized, observer-blinded trial. J Am Acad Dermatol 2002,46(1):73-7
17. Schurmeyer-Horst F, Luger T, Böhm M. Long-term efficacy of occlusive therapy with topical pimecrolimus in severe dyshidrosiform hand and foot eczema. Dermatology 2007;214(1):99-100
18. Belsito DV, Fowler JF Jr, Marks JG Jr, et al. Multicenter Investigator Group. Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. Cutis 2004;73(1):31-8
19. Hanifin JM, Stevens V, Sheth P, Breneman D. Novel treatment of chronic severe hand dermatitis with bexarotene gel. Br J Dermatol 2004;105(3):545-53
20. Scheinfeld N. Schools of pharmacology: retinoid update. J Drugs Dermatol 2006;5(9):921-2
21. Wollina U, Karamfilov T. Adjuvant botulinum toxin A in dyshidrotic hand eczema: a controlled prospective pilot study with left-right comparison. J Eur Acad Dermatol Venereol 2002;16(1):40-2
22. Swarding C, Naver H, Lindberg M, Anveden I. Treatment of dyshidrotic hand dermatitis with intradermal botulinum toxin. J Am Acad Dermatol 2002;47(5):667-71
23. Bansal C, Omlin KJ, Hayes CM, Rohrer TE. Novel cutaneous uses for botulinum toxin type A. J Cosmet Dermatol 2006;5(3):268-72
24. Kontochritopoulos G, Gregoriou S, Agiasofitou G, et al. Regression of relapsing dyshidrotic eczema after treatment of concomitant hyperhidrosis with botulinum toxin-A. Dermatol Surg 2007;33(10):1289-90
25. Glogau RG. Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: results of a randomized, blinded, vehicle-controlled study. Dermatol Surg 2007;33(1 Spec No):S76-80
26. Clinical Trials.gov. Dandelion juice in the treatment of dyshidrotic hand eczema. NCT00442091; 2007. Available from: http://clinicaltrials.gav/ct/gui/show/NCT00442091
27. Wollina U, Abdel Naser MB. Pharmacotherapy of pompholyx Expert Opin Pharmacother 2004;5(7):1517-22
28. Cheer SM, Foster RH. Alitretinoin. Am J Clin Dermatol 2000;1(5):307-14
29. Ruzicka T, Larsen FG, Galewicz D, et al. Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy. Results of a randomized, double-blind, placebo-controlled, multicenter trial. Arch Dermatol 2004;140(12):1453-9
30. Ruzicka T, Lynde CW, Jemec GBE, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized double-blind, placebo-controlled, multicentre trial. Br J Dermatol 2008;158(4):808-17
31. Riccioni G, Bucciarelli T, Mancini B, et al. Antileukotriene drugs: clinical application, effectiveness and safety. Curr Med Chem 2007;14(18):1966-77
32. Woodmansee DP, Simon RA. A pilot study examining the role of zileuton in atopic dermatitis. Ann Allergy Asthma Immunol 1999;83(6 Pt 1):548-52
33. Carucci JA, Washenik K, Weinstein A, et al. The eleukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis. Arch Dermatol 1998;134(7):785-6
34. Yanase DJ, David-Bajar K. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis. J Am Acad Dermatol 2001;44(1):89-93
35. Capella GL, Grigerio E, Altomare G. A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults. Eur J Dermatol 2001;11(3):209-13
36. Nettis E, Pannofino A, Fanelli M, et al. Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta Derm Venereol 2003;83(1):297-320
37. Rahman ML, Choudhury AM, Islam MM. Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Med J 2006;15(1):85-8
38. Friedmann PS, Palmer R, Tan E, et al. A double-blind, placebo-controlled trial of montelukast in adult atopic eczema. Clin Exp Allergy 2007;37(10):1536-40
39. Dastidar SG, Rajagopal D, Ray A. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs 2007;8(5):364-72
40. Bäumer W, Hoppmann J, Rundfeldt C, Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets 2007;6(1):17-26
41. Jacobi A, Antoni C, Manger B, et al. Infliximab in the treatment of moderate to atopic dermatitis. J Am Acad Dermatol 2005;52(3 Pt 1):522-6
42. Harper EG, Simpson EL, Takiguchi RH, et al. Efalizumab therapy for atopic dermatitis causes marked increases in circulating effector memory CD4+ T cells that express cutaneous lymphocyte antigen. J Invest Dermatol 2007 [Epub ahead of print]
43. Takiguchi R, Tofte S, Simpson B, et al. Efalizumab for severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2007;56(2):222-7
44. Ogden S, Clayton TH, Goodfield MJD. Recalcitrant hand pompholyx: variable response to etanercept. Clin Exp Dermatol 2005;31(1):145-6
45. Kägi MK, Heyer G. Efficacy of basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody in a patient with severe chronic atopic dermatitis. Br J Dermatol 2001;145(2):350-1
46. Walker S, Monteil M, Phelan K, et al. Anti-IgE far chronic asthma. Cochrane Database Syst Rev 2003;3:CD003559
47. MacConnachie AA, Smith CC. Pompholyx eczema as a manifestation of HIV infection, response to antiretroviral therapy. Acta Derm Venereol 2007;87(4):378-9
48. Schmidt T, Abeck D, Boeck K, et al. UVA1 irradiation is effective in treatment of chronic vesicular hand eczema. Acta Derm Venereol 1998;78(4):318-9
49. Polderman MC, Govaert JC, le Cessie S, Pavel S. A double-blind placebo-controlled trial of UVA-1 in the treatment of dyshidrotic eczema. Clin Exp Dermatol 2003;28(6):584-7
50. Petering H, Breuer C, Herbst R, et al. Comparision of localized high-dose UVA1 versus topical cream psoralen-UVA for treatment of chronic vesicular dyshidrotic eczema. J Am Acad Dermatol 2004;50(1):68-72
51. Warshaw EM. Therapeutic options for chronic hand dermatitis. Dermatol Ther 2004;17:240-9
52. Stambaugh MD, DeNittis AS, Wallner PE, Heymann WR. Complete remission of refractory dyshidrotic eczema with the use of radiation therapy. Cutis 2000;65(4):211-4
53. Man I, Ibborson SH, Ferguson J. Photoinduced pompholyx: a report of 5 cases. J Am Acad Dermatol 2004;50(1):55-60
54. Krutmann J, Meve-Koenigs K, Ruzicka T, et al. Ultraviolet-free phototherapy. Photodermatol Photoimmunol Photomed 2005;21(2):59-61